Company Encyclopedia
View More
name
ACESO LIFE SCI
00474.HK
Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of construction machinery and spare parts business; provision of repair and maintenance and transportation service business; money lending business; provision of asset management, securities brokerage and other financial service business; property leasing business; and property development business segments. The company leases and sells construction machinery, including crawler cranes, mobile cranes, aerial platforms, and foundation equipment, as well as spare parts; and sells construction materials. It also provides repair and maintenance services for construction machinery; transportation services, such as local container delivery, construction site delivery, and heavy machinery transport; mortgaged and personal loans; and money lending, asset management, commodities, futures, securities brokerage, and other financial services.
97.14 B
00474.HKMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
E
Consumer FinanceIndustry
Industry Ranking28/30
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-67.58%E
    • Profit Margin664.29%A
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-429.41%E
    • Net Profit YoY5.10%C
    • Total Assets YoY-60.69%E
    • Net Assets YoY-77.44%E
  • Cash ScoreD
    • Cash Flow Margin15.05%C
    • OCF YoY-429.41%E
  • Operating ScoreE
    • Turnover-0.02E
  • Debt ScoreE
    • Gearing Ratio78.51%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Performance" ACESO LIFE SCI's mid-term net profit is 386 million yuan, turning from loss to profit

    ACESO LIFE SCI announced its interim results for the six months ended September, with revenue of HKD 29 million, an increase of 26.1% year-on-year. It recorded a net profit of HKD 386 million, compared to a loss of HKD 137 million in the same period last year, turning from loss to profit; earnings per share were HKD 0.0527. No dividend was declared

    AASTOCKS·
    HK
    00474
    -4.03%
    AASTOCKS·
    HK
    00474
    -4.03%

    Morning Trend | ACESO LIFE SCI surges sharply in the short term, is the market watching the main force's unusual movements or is it speculative overheating?

    ACESO LIFE SCI (474.HK) experienced a violent short-term breakout after hours yesterday, with the price surpassing the previous strong resistance of 0.13 HKD. The trading heat during the session was explosive, quickly igniting interest in the biotechnology sector. Short-term bulls dominated, with speculative funds and right-side traders driving rapid increases, resulting in a resonance of volume and price that formed consecutive upward candles. Technical analysis shows that after the MACD golden cross, the momentum bars expanded sharply, and the 5-day and 10-day moving averages rose briefly, while the Bollinger Bands continued to "open," indicating an extremely strong atmosphere for short-term speculation. Time-sharing transactions frequently jumped, with right-side chasing and swing arbitrage funds switching at high frequency, leading to lively discussions in the community. On the fundamental side, the company has not disclosed any new information or policy catalysts, driven purely by sector themes and sentiment. Historical experience shows that once ACESO LIFE SCI experiences significant movements at high levels, it is often accompanied by sharp pullbacks, making quick entry and exit the mainstream strategy for funds. If trading volume cannot be sustained, it may easily trigger a pullback after a rise, and time-sharing anomalies should be closely monitored. Risk warning: Under the crowded effect of speculative funds, those chasing high prices should be cautious of sudden large adjustments caused by poor turnover. If trading volume quickly dries up or there is a significant outflow of main funds during the session, it can easily lead to consecutive pullbacks, so it is advisable to appropriately reduce positions in conjunction with time-sharing, sector heat, and fund rhythm

    Technical Forecast·
    HK
    00474
    -4.03%
    Technical Forecast·
    HK
    00474
    -4.03%

    ACESO LIFE SCI: Fully repaid the outstanding loans to a commercial bank in Hong Kong

    According to the Zhitong Finance APP, ACESO LIFE SCI announced that the company received a demand letter from a commercial bank in Hong Kong on April 23, 2025, requesting repayment of a total debt of approximately HKD 352 million. As of the date of this announcement, the company has fully repaid all outstanding debts

    Zhitong·
    HK
    00474
    -4.03%
    Zhitong·
    HK
    00474
    -4.03%

    Shareholders of ACESO LIFE SCI will transfer their shares from Haitong International Securities to lmagi Brokerage Limited with a transfer value of HKD 124 million

    According to the latest information from the Hong Kong Stock Exchange, on October 9, shareholders of ACESO LIFE SCI transferred their shares from Haitong International Securities to lmagi Brokerage Limited, with a transfer market value of HKD 124 million, accounting for 26.56%. On October 8, shareholders of ACESO LIFE SCI conducted a transfer operation, moving shares from Haitong International Securities to lmagi Brokerage Limited, with a transfer market value of HKD 67.9825 million, accounting for 13.95%. Recently, the company announced refinancing arrangements related to the 2018 financing agreement. All prerequisites under the 2025 loan agreement have been met, and the transaction was completed on September 26, 2025. With the completion of this transaction, the company has been provided with a total financing amount of approximately GBP 87.3 million, of which about GBP 70.3 million has been withdrawn today for the full repayment of the UK loan and related transaction costs. The remaining GBP 17 million will be used for capital expenditures on UK properties in the next one to two years

    Zhitong·
    HK
    00474
    -4.03%
    Zhitong·
    HK
    00474
    -4.03%

    Shareholders of ACESO LIFE SCI will transfer their stocks from Haitong International Securities to lmagi Brokerage Limited with a transfer market value of HKD 67.9825 million

    According to the latest information from the Hong Kong Stock Exchange, on October 8, shareholders of ACESO LIFE SCI transferred their shares from Haitong International Securities to lmagi Brokerage Limited, with a transfer market value of HKD 67.9825 million, accounting for 13.95%. Recently, ACESO LIFE SCI announced the refinancing arrangement related to the 2018 financing agreement. All conditions precedent under the 2025 loan agreement have been met, and the closing was completed on September 26, 2025. With the completion of this closing, the company has been provided with a total financing amount of approximately GBP 87.3 million, of which about GBP 70.3 million has been withdrawn today to fully repay the UK loans and related transaction costs. The remaining GBP 17 million will be used for capital expenditures on UK properties over the next one to two years. The company will begin planning a major renovation project for its UK properties, including upgrading its main facilities and supporting facilities, in order to enhance the rental income and capital value of the UK properties

    Zhitong·
    HK
    00474
    -4.03%
    Zhitong·
    HK
    00474
    -4.03%
    © 2025 Longbridge｜Disclaimer